Debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogues

European Journal of Endocrinology

Volumn 152, Issue 5, 2005, Pages 693-694

  Wass, John ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE; LONG ACTING DRUG; OCTREOTIDE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; CYTOREDUCTIVE SURGERY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; GROWTH HORMONE BLOOD LEVEL; HORMONAL REGULATION; HUMAN; HYPOPHYSIS ADENOMA; NOTE; POSTOPERATIVE CARE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SURGICAL APPROACH; SURGICAL TECHNIQUE; TREATMENT OUTCOME;

ACROMEGALY; ADENOMA; COMBINED MODALITY THERAPY; HUMANS; PITUITARY NEOPLASMS; SOMATOSTATIN;

EID: 19744370908     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.01896     Document Type: Note

References (11)

1. Petrossians P, Borges-Martins L, Espinoza C, Daly A, Betea D, Valdes-Socin H, Stevenaert A, Chanson P & Beckers A. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. European Journal of Endocrinology 2005 152 61-66.
2. Wass JAH, Turner HE & Adams CBT. The importance of locating a good pituitary surgeon. Pituitary 1999 2 51-54.
3. Ahmed S, Elsheikh M, Page RCL, Adams CBT & Wass JAH. Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience. Clinical Endocrinology 1999 50 561-567.
4. Fahlbusch R, Buchfelder M, Kreutzer EJ & Nomikos P. Surgical management of acromegaly. In Handbook of Acromegaly. Ed J Wass. Bristol: BioScientifica, 2001.
5. Ciccarelli E, Corsello SM, Plowman PN, Jones AE, Touzel E, Rees LH, Besser GM & Wass JAC. Long-term effects of radiotherapy for acromegaly on circulating prolactin. Acta Endocrinologica 1989 121 827-832.
6. Bevan JS, Atkin SL, Atkinson AB, Bouloux P-M, Hanna F, Harris PE, James RA, McConnell M, Roberts GA, Scanlon MF, Stewart PM, Teasdale E, Turner HE, Wass JAH & Wardlaw JM. Primary medical therapy for acromegaly: an open prospective, multicentre study of subcutaneous and intramuscular slow-release Octreotide on GH, IGF-1 and tumour size. Journal of Clinical Endocrinology and Metabolism 2002 87 4554-4563.
7. Ayuk J, Stewart SE, Stewart PM, Sheppard MC & European Sandostatin LAR Group. Efficacy of Sandostatin LAR (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy. Clinical Endocrinology 2004 60 375-381.
8. Freda PU & Wardlaw SL. Primary medical therapy for acromegaly. Journal of Clinical Endocrinology and Metabolism 1998 83 3031-3033.
9. Ashwell SG, Bevan JS, Edwards OM, Harris MM, Holmes C, Middleton MA & James RA. The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octrestide LAR. European Journal of Endocrinology 2004 150 473-480.
10. Turner HE, Vadivale A, Keenan J & Wass JAH. A comparison of lanreotide and octreotide LAR for treatment of acromegaly. Clinical Endocrinology 1999 51 275-280.
11. Ashwell SG, Bevan JS, Edwards OM, Harris MM, Holmes C, Middleton MA & James RA. The efficacy and safety of lanreotide autogel in patients with acromegaly previously treated with octreotide LAR. European Journal of Endocrinology 2004 150 473-480.